Eye on Earnings: Exact Sciences

Exact Sciences CEO: $2.8 billion Genomic Health deal can yield $1.6 billion in revenueПодробнее

Why Exact Sciences Has More Upside (Even Though It’s Up 20% Today)Подробнее

MD Explains Exact Sciences -- Beating Colon Cancer at home with Cologuard (EXAS stock)Подробнее

Citron's Left on Exact Sciences Short, Blood-Based TechПодробнее

Exact Sciences cuts about 5% of workforce, including in WisconsinПодробнее

Exact Sciences swoops in to buy bioscience company that faced shutdownПодробнее

Exact Sciences CEO: Life Changing Stock | Mad Money | CNBCПодробнее

Exact Sciences CEO: Detecting Cancer | Mad Money | CNBCПодробнее

Why Exact Sciences Is Up 16% Today (More Upside Coming?)Подробнее

DON'T BUY Exact Sciences Stock (Until You Watch This Analysis) #EXASПодробнее

Exact Sciences CEO: A Positive 2017 | Mad Money | CNBCПодробнее

Best Ideas 2023: Exact Sciences Corporation [EXAS]Подробнее

Exact Sciences CEO on addressing needs for early stage cancer screeningПодробнее

Exact Sciences (Stock : EXAS) CFO Jeff Elliott interview on Business Outlook and Growth.Подробнее

[EXAS stock] Exact Sciences Q4 2020 Earnings Call (2/16/21)Подробнее

Citron's Left Calls Exact Sciences a 'Marketing Company'Подробнее

Exact Sciences CEO explains new cancer screening testПодробнее

Exact Sciences plans $350 million expansion, 1,300 new jobs, in MadisonПодробнее

Exact Sciences 3rd Quarter 2022 Earnings CallПодробнее